Mainstream supplement brand
Hims is a telehealth platform selling both prescription products (dispensed after an online clinician review, including compounded GLP-1 medications and hair-loss treatments) and non-prescription over-the-counter wellness and supplement products, under one consumer brand.
quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
A mix of prescription telehealth products (hair loss, sexual health, weight management) and over-the-counter supplements and personal care products.
Hims sells both prescription and non-prescription products on the same platform. Prescription items require a licensed clinician's review before dispensing and are not the same regulatory category as an over-the-counter supplement; read each product page carefully to know which category applies. Nothing here is medical advice.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
Hims' own site distinguishes compounded from brand-name options in places; compounded drugs are not FDA-approved in the same way brand-name drugs are, a distinction worth reading carefully on the specific product page rather than assuming from the category name.
Where the vendor states thisAs with other telehealth brands offering compounded medications, these are not reviewed by FDA for safety, effectiveness or quality the way an approved drug is; this applies to the compounded options specifically, not necessarily to every Hims product.
No. Hims sells both prescription items dispensed after clinician review and over-the-counter supplements; check the specific product page to see which applies.
Every fact above traces to one of these pages, published by the vendor itself and checked on September 29, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate
